Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IQVIA Holdings Inc. (NYSE: IQV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. IQVIA’s filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV.
IQVIA uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements and leadership or board changes. For example, the company has filed 8-K reports describing financial results for specific quarters, an amendment to its Fifth Amended and Restated Credit Agreement and the planned transition of its chief financial officer. Other 8-K filings cover the appointment of new directors and related governance matters.
For investors analyzing IQVIA, these filings help explain the company’s financial condition, capital structure and key corporate developments. They also provide context for IQVIA’s role as a global provider of clinical research services, commercial insights and healthcare intelligence, including how it finances its operations and manages governance and leadership transitions.
On Stock Titan, SEC filings for IQVIA are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries help interpret lengthy filings by highlighting important sections, such as descriptions of material agreements, financial updates or changes in executive roles. Users can review 8-Ks for event-driven information and refer to other filing types, such as annual and quarterly reports when available, to gain a more complete view of IQVIA’s business and risks.
IQVIA Holdings executive James G. Berkshire received a stock appreciation right award covering 11,180 shares of common stock. The award was granted on February 9, 2026 at an exercise price of $192.67 per share and expires on February 9, 2036.
The stock appreciation right vests in three equal annual installments beginning on February 9, 2027. Following this grant, Berkshire beneficially owns 11,180 derivative securities directly, in his role as EVP, Global Infrastructure and Operations.
IQVIA Holdings Inc. Director and Chairman, Chief Executive Officer & President Ari Bousbib reported receiving a grant of stock appreciation rights on February 9, 2026. The award covers 78,264 derivative securities tied to the company’s common stock at a conversion or exercise price of $192.67 per share.
The stock appreciation right vests in three equal annual installments beginning on February 9, 2027, meaning the right becomes exercisable over a three-year period rather than all at once. Following this grant, Bousbib directly holds 78,264 stock appreciation rights related to IQVIA common stock.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Leslie Wims Morris received a grant of 159 deferred share units on February 9, 2026. Each deferred share is convertible into one share of common stock upon settlement under the company’s Non-Employee Director Deferral Plan. Settlement occurs when Morris ceases to be a director, upon a change in control of the company, or upon death, and there is no expiry date. Following this grant, Morris directly beneficially owns 4,894 deferred share units.
IQVIA Holdings Inc. director Colleen A. Goggins received an equity-based award in the form of deferred shares. On 02/09/2026, she acquired 198 deferred shares at a reference price of $192.67 per deferred share, bringing her directly owned deferred share balance to 4,900.
Each deferred share converts into one share of IQVIA common stock upon settlement. According to the company’s Non-Employee Director Deferral Plan, settlement occurs when the director leaves the board, a change in control happens, or upon the director’s death, and the award has no expiry date.
IQVIA Holdings director Jim Fasano reported an acquisition of deferred share units tied to company stock. On 02/09/2026, he received a grant of 211 deferred shares at a reported price of $192.67 per unit, increasing his directly held deferred shares to 4,274.
Each deferred share converts into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, these units generally settle when he ceases to be a director, upon a change in control of the company, or upon his death, and they have no expiration date.
IQVIA Holdings Inc. director John G. Danhakl received a grant of 172 deferred share units on February 9, 2026. The grant is valued at $192.67 per deferred share and increases his directly held deferred shares to 2,944.
Each deferred share converts into one share of IQVIA common stock upon settlement, which occurs under the company’s Non-Employee Director Deferral Plan when he ceases to be a director, upon a change in control of the company, or upon his death. The deferred shares have no expiration date.
IQVIA Holdings executive Bernd Haas reported equity-based compensation activity. On February 8, 2026, he acquired 8,265 shares of common stock at $0 upon achievement of performance goals tied to restricted stock units granted in 2023. The company’s Leadership Development and Compensation Committee certified that these performance conditions were satisfied on that date. On the same day, 440 shares were withheld at a price of $187.49 to cover obligations associated with the award, leaving Haas with 24,414 IQVIA common shares held directly following the transactions. He serves as EVP, AI and Technology Solutions.
IQVIA Holdings Inc. officer Alistair Grenfell reported equity compensation activity involving the company’s common stock. On February 8, 2026, he acquired 11,795 shares of common stock at $0 per share, bringing his holdings to 29,669 shares directly owned.
On the same date, a separate transaction coded F covered the disposition of 5,545 shares at $187.49 per share, after which he directly owned 24,124 shares of IQVIA common stock. The acquired shares were delivered upon achievement of performance conditions under performance-based restricted stock units granted on February 13, 2023.
IQVIA Holdings executive Michael J. Fedock reported equity transactions in company common stock. On February 8, 2026, he acquired 6,735 shares at $0, tied to performance-based restricted stock units whose conditions were confirmed achieved by the Leadership Development and Compensation Committee.
Fedock also disposed of 111 shares on February 7, 2026 and 2,420 shares on February 8, 2026, each at a price of $187.49 per share. After these transactions, he directly beneficially owned 9,595 shares of IQVIA common stock.
IQVIA Holdings officer Bhavik Patel reported equity award activity in company stock. On February 8, 2026, he acquired 4,083 shares of common stock at a price of $0, following satisfaction of performance conditions tied to performance-based restricted stock units granted on February 13, 2023.
On the same date, a separate transaction reduced his direct holdings by 1,920 shares at $187.49 per share, leaving him with 3,203 shares of IQVIA common stock held directly.